Zhen Su

Zhen Su is the CEO of Marengo Therapeutics, a Cambridge biotech reprogramming T cells to wake up the immune system against cancer. A physician-scientist with nearly three decades in oncology, he ran a billion-dollar global cancer franchise at Merck KGaA, helped deliver eight regulatory approvals as CMO of EMD Serono, and now steers Marengo's STAR platform into the clinic on the back of a $2.8B Ipsen partnership.